These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 5577947)
1. [Use of intravenous melphalan in the treatment of Kahler's disease]. Balmes A; Dauverchain J; Othoniel J; Mandin A; Chavanette F Presse Med (1893); 1971 May; 7(23):1072. PubMed ID: 5577947 [No Abstract] [Full Text] [Related]
2. [Value of intravenous Melphalan in treatment of Kahler's disease]. Balmes A; Dauverchain J; Mandin A; Othoniel J; Vedel A Mars Med; 1969; 106(6):505-8. PubMed ID: 5376451 [No Abstract] [Full Text] [Related]
3. [Prognosis of Kahler's disease in patients treated and not treated with alkylating agents (apropos of 45 cases)]. Saporta L; Hugon C; Rondier J; Bontoux D; Delbarre F Rev Rhum Mal Osteoartic; 1972 Jan; 39(1):11-8. PubMed ID: 5079686 [No Abstract] [Full Text] [Related]
4. [Comparative study of the melphalan and of the cyclophosphamide in the treatment of Kahler's disease]. Bontoux D; Chenbit D; Delbarre F Therapeutique; 1971 Jan; 47(1):27-32. PubMed ID: 5572915 [No Abstract] [Full Text] [Related]
5. [High-dose melphalan in patients with multiple myeloma]. Moreau P; Le Bonniec M; Harousseau JL Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762 [TBL] [Abstract][Full Text] [Related]
6. [Skin lesions as a rare initial symptom of Kahler's disease]. van Tol KM; Fedder G Ned Tijdschr Geneeskd; 1994 Mar; 138(10):526-8. PubMed ID: 8139713 [TBL] [Abstract][Full Text] [Related]
7. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure. Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285 [TBL] [Abstract][Full Text] [Related]
8. [Ophthalmoplegia revealing Kahler's disease]. Ardouin M; Urvoy M; Eon JY; Le Blay R Bull Soc Ophtalmol Fr; 1978 Dec; 78(12):897-9. PubMed ID: 755570 [No Abstract] [Full Text] [Related]
9. Pharmacology of intravenous melphalan in patients with multiple myeloma. Brox L; Birkett L; Belch A Cancer Treat Rev; 1979 Jun; 6 Suppl():27-32. PubMed ID: 498169 [No Abstract] [Full Text] [Related]
10. [Treatment of multiple myeloma with melphalan: 35 personal cases]. Dryll A; Ryckewaert A; Kahn MF; Hayat M; de Seze S Sem Hop; 1970 Jan; 46(5):289-98. PubMed ID: 4327260 [No Abstract] [Full Text] [Related]
11. Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study. Offidani M; Marconi M; Corvatta L; Olivieri A; Catarini M; Leoni P Haematologica; 2003 Dec; 88(12):1432-3. PubMed ID: 14688003 [No Abstract] [Full Text] [Related]
12. [Ulcero-necrotic purpura revealing Kahler's disease, with macroglobulinemia]. Bureau Y; Barrière H; Senelar R; Litoux P; Bureau B Bull Soc Fr Dermatol Syphiligr; 1967; 74(4):495-8. PubMed ID: 4967360 [No Abstract] [Full Text] [Related]
13. Short course intermediate dose intravenous melphalan therapy in myeloma--relation to early emergence of drug resistance (phase II study). Sviland L; Leggat H; Harris AL; Bird G; Proctor SJ Acta Haematol; 1987; 78(4):233-8. PubMed ID: 3122488 [TBL] [Abstract][Full Text] [Related]